Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coca-Cola
KO
|
+$32.8M |
| 2 |
Apple
AAPL
|
+$32.1M |
| 3 |
ArriVent BioPharma
AVBP
|
+$31.5M |
| 4 |
argenx
ARGX
|
+$26.4M |
| 5 |
CRH
CRH
|
+$25.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$55.4M |
| 2 |
Royalty Pharma
RPRX
|
+$48.3M |
| 3 |
Las Vegas Sands
LVS
|
+$36.3M |
| 4 |
Microsoft
MSFT
|
+$33.4M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$29.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.68% |
| 2 | Technology | 7.85% |
| 3 | Communication Services | 7.05% |
| 4 | Consumer Discretionary | 4.46% |
| 5 | Financials | 3.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Avantor
AVTR
$9.78B
| $1.84M | 0.07% |
71,850
+33,600
| +88% | +$799K |
|
77
IQVIA
IQV
$42.8B
| $1.81M | 0.07% |
7,175
| – | – |
|
|
MOLN
78
Molecular Partners
MOLN
$165M
| $1.68M | 0.06% |
400,000
| – | – |
|
79
Stryker
SYK
$126B
| $1.56M | 0.06% |
4,360
| – | – |
|
80
Medtronic
MDT
$119B
| $1.52M | 0.06% |
17,460
| – | – |
|
|
LKFT
81
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $1.52M | 0.06% |
47,200
| – | – |
|
82
CVS Health
CVS
$119B
| $1.37M | 0.05% |
17,170
| – | – |
|
83
Illumina
ILMN
$33.1B
| $1.2M | 0.04% |
8,974
| – | – |
|
|
AKLI
84
DELISTED
Akili Inc
AKLI
| $1.11M | 0.04% |
3,841,718
| – | – |
|
85
Waters Corp
WAT
$40.4B
| $1.08M | 0.04% |
3,150
| – | – |
|
86
Benitec Biopharma
BNTC
$463M
| $1.07M | 0.04% |
204,220
| – | – |
|
87
HCA Healthcare
HCA
$92.9B
| $1.06M | 0.04% |
+3,190
| New | +$975K |
|
88
Edwards Lifesciences
EW
$51.8B
| $1.06M | 0.04% |
+11,100
| New | +$932K |
|
89
Protagonist Therapeutics
PTGX
$9.99B
| $882K | 0.03% |
+30,500
| New | +$830K |
|
90
DexCom
DXCM
$34.8B
| $816K | 0.03% |
5,880
| – | – |
|
91
Agilent Technologies
A
$44.9B
| $726K | 0.03% |
4,990
| – | – |
|
92
Morgan Stanley
MS
$336B
| $719K | 0.03% |
7,641
+2,841
| +59% | +$250K |
|
93
Humana
HUM
$45.5B
| $676K | 0.03% |
+1,950
| New | +$739K |
|
94
Veralto
VLTO
$24.1B
| $485K | 0.02% |
5,475
| – | – |
|
95
ResMed
RMD
$33.4B
| $473K | 0.02% |
+2,390
| New | +$438K |
|
96
Ionis Pharmaceuticals
IONS
$9.93B
| $468K | 0.02% |
+10,800
| New | +$515K |
|
97
Zimmer Biomet
ZBH
$19.3B
| $430K | 0.02% |
+3,260
| New | +$407K |
|
98
Align Technology
ALGN
$11.5B
| $361K | 0.01% |
+1,100
| New | +$323K |
|
99
Steris
STE
$23.2B
| $344K | 0.01% |
+1,530
| New | +$345K |
|
100
Baxter International
BAX
$13.6B
| $341K | 0.01% |
+7,970
| New | +$324K |
|
Similar funds
Aaron Cowen's Q1 2024 Portfolio in Review
As of Q1 2024, Aaron Cowen held 113 positions worth $2.69B, up 22% from $2.21B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Aaron Cowen deployed $129M of net new capital in Q1 2024, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Coca-Cola: 546,500 shares worth $33.4M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 70% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Arcellx, an estimated $55.4M trimmed.
- Aaron Cowen's largest Q1 2024 buy was Coca-Cola: 546,500 shares worth $33.4M.
- Aaron Cowen added most to argenx in Q1 2024, an estimated $26.4M increase.
- Aaron Cowen's biggest Q1 2024 reduction was Arcellx, cutting an estimated $55.4M.
- Aaron Cowen fully exited Las Vegas Sands in Q1 2024, selling an estimated $36.3M.
- Aaron Cowen's ten largest holdings make up 44% of its $2.69B portfolio in Q1 2024.
- Aaron Cowen opened 25 new positions and closed 12 in Q1 2024.
- Aaron Cowen's portfolio value rose 22% quarter-over-quarter to $2.69B.
Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.